Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

South Rampart Pharma to Present at 2023 BIO CEO & Investor Conference


Hernan Bazan, MD, FACS, CEO and Co-Founder, will provide a company update

Dr. Bazan will also participate in a panel on pain therapeutics innovation with a VP of Industry Research from BIO and Program Directors from NIH and the U.S. Pain Foundation

NEW ORLEANS, Jan. 31, 2023 /PRNewswire/ -- South Rampart Pharma ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative non-opioid medications for the treatment of pain, today announced that Hernan Bazan, MD, FACS, CEO and Co-Founder of South Rampart Pharma and the Endowed John Ochsner Professor of Cardiovascular Innovation at the Ochsner Clinic, will present at the BIO CEO & Investor Conference on Monday, February 6.

Dr. Bazan's presentation will highlight the recent company developments on its novel non-opioid lead asset, ongoing pipeline progress, clinical trial updates and anticipated milestones. Details about the presentation are as follows:

Presenter: Hernan Bazan, MD, FACS, CEO and Co-Founder of South Rampart Pharma
Date: Monday, February 6, 2023, at 2:15 p.m. EST
Location: Winter Garden Room, Marriott Marquis, New York, NY
Registration: Here

Dr. Bazan will also participate in a panel discussion titled "Resetting the innovation landscape for pain and addiction therapeutics" on Tuesday, February 7, 2023, from 9 a.m. to 9:45 a.m. EST. The panel will also include a Program Director from The National Institutes of Health (NIH)/NINDS, a Vice President of Industry Research at Biotechnology Innovation Organization (BIO), and the National Director of Policy and Advocacy from the U.S. Pain Foundation. More information can be found here.

Dr. Bazan and Josh Blacher, CFO, will be available for one-on-one investor meetings with registered conference attendees. Meetings can be scheduled via the BIO One-on-One Partnering system: https://www.bio.org/events/bio-ceo-investor-conference/bio-one-one-partneringtm 

About South Rampart Pharma

South Rampart Pharma is a clinical-stage life science company dedicated to advancing the safe treatment of pain by developing new non-opioid small molecule solutions that lack the liver and kidney toxicity present in current pain medicines. The Company's lead program, SRP-001, currently in a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics [ClinicalTrials.gov Identifier: NCT05484414 with data expected in 2023.

Please visit the Company's website and connect with us on Twitter and LinkedIn for more information.

Media Relations

Ignacio Guerrero-Ros, Ph.D.

Russo Partners

[email protected]

646-942-5604

Investor Relations:

Adanna G. Alexander, Ph.D.

Russo Partners

[email protected]

646-942-5603

SOURCE South Rampart Pharma


These press releases may also interest you

at 03:22
A news report from iChongqing: In 2014, Chinese President Xi Jinping and Germany's then Vice Chancellor and Minister of Economics and Energy, Sigmar Gabriel, witnessed the arrival of the YUXINOU (Chongqing-Xinjiang-Europe) train in Duisburg, Germany....

at 03:05
VIAVI Solutions ("VIAVI") notes the announcement made by Keysight Technologies, Inc. ("Keysight") and Spirent Communications plc ("Spirent") on March 28, 2024, of a recommended cash acquisition of Spirent by Keysight. VIAVI believes that its...

at 03:04
Policybazaar, India's leading online insurance marketplace, is witnessing a significant increase in non-resident Indians (NRIs) choosing term insurance from India via its platform. This surge is driven by the unparalleled ease, affordability and...

at 03:00
TRON Forum (Chair: Ken Sakamura, Professor Emeritus of the University of Tokyo) is pleased to announce that four microcontroller manufacturers, Infineon Technologies Japan K.K. (President & CEO: Ikuya Kawasaki), STMicroelectronics K.K. (Country...

at 02:00
OKX, a leading crypto exchange by trading volume and a leading Web3 technology company, has issued updates for March 29, 2024. OKX...

at 00:30
Frost & Sullivan recently researched the data center colocation services industry and, based on its findings, recognizes STT GDC India with the 2023 Indian Company of the Year Award. STT GDC India is a pioneer data center solutions provider that...



News published on and distributed by: